Monday, November 18, 2024
- 10:30AM-12:30PM
-
Abstract Number: 2351
Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
SpA Including PsA – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2270
Low Yield of Routine Serological Screening for Hepatitis B in Patients with Rheumatoid Arthritis Starting Rituximab Therapy in a Non-Endemic Country
RA – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 1838
M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster- 10:30AM-12:30PM
-
Abstract Number: 2469
Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
Systemic Sclerosis & Related Disorders – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 1908
Male Sex, Medical Comorbidity and Post-procedure Complications Are Associated with Higher In-hospital Mortality After Primary Total Knee Arthroplasty for Osteoarthritis
Healthcare Disparities in Rheumatology Poster III- 10:30AM-12:30PM
-
Abstract Number: 1844
Manufacturing of IMPT-514, a CD19/CD20 Bispecific CAR T Cell Product Candidate as a Potential Treatment of Patients with Autoimmune Diseases
T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster- 10:30AM-12:30PM
-
Abstract Number: 2233
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 1809
Melanocytes Are Driven Toward an Antigen Presentation Phenotype Through UV-Induced Keratinocyte Crosstalk and Exposure to Type I Interferons in Patients with Cutaneous Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster- 10:30AM-12:30PM
-
Abstract Number: 1788
Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster- 10:30AM-12:30PM
-
Abstract Number: 2330
Mental Health, Sex, and Comorbidities as Determinants of Recalcitrant PsA
SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2479
Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Vasculitis – ANCA-Associated Poster III- 10:30AM-12:30PM
-
Abstract Number: 2524
Metabolite Profiling of Saliva for the Discrimination of Behcet’s Disease, Sjogren’s Syndrome, and Recurrent Aphthous Stomatitis